Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2023 18:48 ET | Source: Sorrento Therapeutics, Inc.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine

ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The acute migraine drug market size is...
February 04, 2023 22:48 ET | Source: Sorrento Therapeutics, Inc.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders

PALO ALTO, Calif., Feb. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), an...
February 03, 2023 20:59 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock

SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today distributed dividend confirmation statements to 146 brokerage firms regarding its recent...
February 02, 2023 14:12 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Issues Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

SAN DIEGO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a supplement to its previously issued “Frequently Asked Questions” document under the...
February 02, 2023 13:15 ET | Source: Sorrento Therapeutics, Inc.

Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

PALO ALTO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today...
January 29, 2023 22:27 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

SAN DIEGO, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a “Frequently Asked Questions” document under the “Investors” section of its website...
January 29, 2023 21:55 ET | Source: Sorrento Therapeutics, Inc.

Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

PALO ALTO, Calif., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today...
January 09, 2023 09:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting

Topline safety, antiviral effectiveness and pharmacokinetic (PK) data from a Phase 1b Study in China are released from the single ascending dose (SAD) portion of the study with the doses from 300 mg...
December 06, 2022 09:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus

Modified mRNA sequence of the Spike protein prevents cleavage of the expressed protein, which may potentially result in a cleaner safety profile.Pre-clinical data supporting the investigational new...
December 05, 2022 15:01 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)

IMC-001, a PD-L1 monoclonal antibody selected from Sorrento’s G-MAB library, demonstrated impressive therapeutic effects in patients with heavily treated NK/T-cell lymphoma with a 60% objective...